JP7082544B2 - Method for eliminating bubbles generated in the reagent for measuring complement value and the reagent for measuring complement value - Google Patents

Method for eliminating bubbles generated in the reagent for measuring complement value and the reagent for measuring complement value Download PDF

Info

Publication number
JP7082544B2
JP7082544B2 JP2018143852A JP2018143852A JP7082544B2 JP 7082544 B2 JP7082544 B2 JP 7082544B2 JP 2018143852 A JP2018143852 A JP 2018143852A JP 2018143852 A JP2018143852 A JP 2018143852A JP 7082544 B2 JP7082544 B2 JP 7082544B2
Authority
JP
Japan
Prior art keywords
reagent
polyalkylene glycol
sensitized
measuring
complement value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018143852A
Other languages
Japanese (ja)
Other versions
JP2020020639A (en
Inventor
公彦 高野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denka Co Ltd
Original Assignee
Denka Co Ltd
Denki Kagaku Kogyo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denka Co Ltd, Denki Kagaku Kogyo KK filed Critical Denka Co Ltd
Priority to JP2018143852A priority Critical patent/JP7082544B2/en
Publication of JP2020020639A publication Critical patent/JP2020020639A/en
Application granted granted Critical
Publication of JP7082544B2 publication Critical patent/JP7082544B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Description

本発明は、補体価測定用試薬及び補体価測定用試薬に生じる泡沫の消去方法に関する。 The present invention relates to a reagent for measuring complement value and a method for eliminating bubbles generated in the reagent for measuring complement value.

ウイルス、細菌等の病原体に対する補体結合性抗体は、病原体が感染するとその補体価は上昇又は下降する。補体価の測定は、各種疾患における診断や治療効果の判断及び免疫能力の指標として重要なものとなっている。 Complement-binding antibodies against pathogens such as viruses and bacteria increase or decrease in complement titer when infected with the pathogen. The measurement of complement titer is important as an index of diagnosis, judgment of therapeutic effect and immune ability in various diseases.

従来の補体価測定方法では、ヒツジ赤血球に抗ヒツジ赤血球抗体を結合させた感作ヒツジ赤血球、および至適倍数に段階希釈した補体を含む溶液(血清など)とを混合して37℃6分間反応させ、補体の作用によって赤血球が破裂した結果溶液中に漏出する赤血球中のヘモグロビンを吸光度法により測定することによって、赤血球の溶血率をグラフより計算し補体価を求めるメイヤー法が一般的であった。近年では、ヘモグロビンを測定する替わりに、残存赤血球の濁度を光学的に測定することにより赤血球の溶血率を計算し補体価を求める自動化学分析装置で測定するオート法が一般的になってきている(特許文献1)。オート法では自動化学分析装置に予め撹拌した試薬をセットして測定するが、試薬をセットしてから測定までの時間が長い場合には、試薬中の赤血球が徐々に沈降する。その結果、そのまま自動分析装置が試薬を採取すると、測定に必要な所定量の赤血球を採取できず正確に測定することができなかった。したがって、正確な測定を行うためには測定直前に、又は測定の間隔が空いた場合に、その都度試薬を撹拌する必要があり、測定作業が煩雑であった。 In the conventional complement valence measurement method, sensitized erythrocyte erythrocytes in which an anti-sheep erythrocyte antibody is bound to sheep erythrocytes and a solution containing complement gradually diluted to the optimum multiple (serum, etc.) are mixed and mixed at 37 ° C. 6 The Mayer method is generally used to calculate the hemolytic rate of erythrocytes from a graph and obtain the complement value by measuring the hemoglobin in the erythrocytes that leaks into the solution as a result of the rupture of the erythrocytes due to the action of complement after reacting for a minute by the absorbance method. It was a target. In recent years, instead of measuring hemoglobin, an automatic method of measuring the hemolysis rate of red blood cells by optically measuring the turbidity of residual red blood cells and measuring the complement value with an automatic chemical analyzer has become common. (Patent Document 1). In the automatic method, a reagent that has been stirred in advance is set in an automatic chemical analyzer for measurement, but if the time from setting the reagent to measurement is long, the red blood cells in the reagent gradually settle. As a result, when the automatic analyzer collected the reagent as it was, the predetermined amount of red blood cells required for the measurement could not be collected and the measurement could not be performed accurately. Therefore, in order to perform accurate measurement, it is necessary to stir the reagent immediately before the measurement or when there is an interval between measurements, which makes the measurement work complicated.

測定の都度に試薬を撹拌すると、試薬に泡沫が発生する。その結果、試薬を採取する際に液面に泡沫が発生することで自動化学分析装置が試薬の液面を正しく感知できず、測定に必要な所定量の試薬を正確に採取できないことがある。また分析用セルに泡沫が残留することで検出感度や再現性の低下を生じるという問題があった。 When the reagent is agitated for each measurement, bubbles are generated in the reagent. As a result, bubbles are generated on the liquid surface when the reagent is collected, so that the automatic chemical analyzer cannot correctly detect the liquid level of the reagent, and the predetermined amount of reagent required for measurement may not be accurately collected. In addition, there is a problem that the detection sensitivity and reproducibility are deteriorated due to the residual foam in the analysis cell.

特開2004-301612号公報Japanese Unexamined Patent Publication No. 2004-301612

本発明の目的は、試薬を撹拌した際に発生する泡沫を速やかに消去することができる補体価測定用試薬を提供することである。 An object of the present invention is to provide a reagent for measuring complement value, which can quickly eliminate bubbles generated when the reagent is stirred.

本願発明者らは、鋭意研究の結果、従来の補体価測定用試薬にポリアルキレングリコールを配合することにより試薬を撹拌して泡沫が発生しても速やかに消去されることを見出し、本発明を完成した。 As a result of diligent research, the inventors of the present invention have found that by adding polyalkylene glycol to a conventional reagent for measuring complement value, the reagent is stirred and even if foam is generated, it is quickly eliminated. Was completed.

すなわち、本願発明は、以下のものを提供する。
(1) 緩衝液中に懸濁された感作赤血球または感作リポソームを含む補体価測定用試薬において、ポリアルキレングリコール(ポリエチレングリコールを除く)を含むことを特徴とする補体価測定用試薬。
(2) 前記ポリアルキレングリコールがポリオキシプロピレングリコールである(1)記載の試薬。
(3) 前記ポリアルキレングリコールの濃度が、試薬全量(感作赤血球または感作リポソームを除く)を基準として0.0005重量%以上である(1)又は(2)記載の試薬。
(4) 消泡剤としてポリアルキレングリコールを緩衝液に添加することから成る、緩衝液中に懸濁された感作赤血球または感作リポソームを含む補体価測定用試薬に生じる泡沫の消去方法。
(5) 前記ポリアルキレングリコールがポリオキシプロピレングリコールである(4)記載の方法。
(6) 前記ポリアルキレングリコールの濃度が試薬全量(感作赤血球または感作リポソームを除く)を基準として0.0005重量%以上である(4)又は(5)記載の方法。
(7) 緩衝液中にポリアルキレングリコール(ポリエチレングリコールを除く)を含んでなる、補体価測定用希釈液。
(8) 前記ポリアルキレングリコールがポリオキシプロピレングリコールである(7)記載の検体希釈液。
(9) 前記ポリアルキレングリコールの濃度が、検体希釈液全量を基準として0.0005重量%以上である(7)又は(8)記載の検体希釈液。

That is, the present invention provides the following.
(1) A reagent for measuring complement value containing sensitized erythrocytes or sensitized liposomes suspended in a buffer solution, which comprises polyalkylene glycol (excluding polyethylene glycol) . ..
(2) The reagent according to (1), wherein the polyalkylene glycol is polyoxypropylene glycol.
(3) The reagent according to (1) or (2), wherein the concentration of the polyalkylene glycol is 0.0005% by weight or more based on the total amount of the reagent (excluding sensitized erythrocytes or sensitized liposomes).
(4) A method for eliminating foam generated in a complement titer measuring reagent containing sensitized erythrocytes or sensitized liposomes suspended in a buffer solution, which comprises adding polyalkylene glycol as a defoaming agent to the buffer solution.
(5) The method according to (4), wherein the polyalkylene glycol is polyoxypropylene glycol.
(6) The method according to (4) or (5), wherein the concentration of the polyalkylene glycol is 0.0005% by weight or more based on the total amount of the reagent (excluding sensitized erythrocytes or sensitized liposomes).
(7) A diluted solution for measuring complement value, which contains polyalkylene glycol (excluding polyethylene glycol ) in a buffer solution.
(8) The sample diluent according to (7), wherein the polyalkylene glycol is polyoxypropylene glycol.
(9) The sample diluent according to (7) or (8), wherein the concentration of the polyalkylene glycol is 0.0005% by weight or more based on the total amount of the sample diluent.

下記実施例及び比較例により実験的に示された通り、本発明の補体価測定用試薬を用いると、試薬を撹拌した際に発生する泡沫を速やかに消去することができる。従って、本発明の試薬を用いると、液面に泡沫が発生することで自動化学分析装置が試薬の液面を正しく感知できず、測定に必要な所定量の試薬を正確に採取できない問題を回避することができ、また分析用セルに泡沫が残留しないため、泡沫に起因する検出感度や再現性の低下を防止することができるので、補体価の自動測定に有利である。 As experimentally shown by the following Examples and Comparative Examples, when the reagent for measuring complement value of the present invention is used, bubbles generated when the reagent is stirred can be quickly eliminated. Therefore, when the reagent of the present invention is used, it is possible to avoid the problem that the automatic chemical analyzer cannot correctly detect the liquid level of the reagent due to the generation of foam on the liquid surface and cannot accurately collect the predetermined amount of the reagent required for measurement. In addition, since foam does not remain in the analysis cell, it is possible to prevent deterioration of detection sensitivity and reproducibility due to foam, which is advantageous for automatic measurement of complement value.

下記実施例5において得られた検量線を示す。The calibration curve obtained in Example 5 below is shown. 下記実施例6において得られた検量線を示す。The calibration curve obtained in Example 6 below is shown. 下記実施例7において得られた検量線を示す。The calibration curve obtained in Example 7 below is shown. 下記実施例8において得られた検量線を示す。The calibration curve obtained in Example 8 below is shown. 下記実施例9において得られた検量線を示す。The calibration curve obtained in Example 9 below is shown. 下記実施例10において得られた検量線を示す。The calibration curve obtained in Example 10 below is shown.

上記の通り、本発明の補体価測定用試薬は、試薬を測定直前に撹拌して泡沫が発生しても、速やかに消去することを可能とするために、試薬中にポリアルキレングリコールを含むことを特徴とする。ポリアルキレングリコールとしては、ポリオキシプロピレングリコールが好ましい。ポリオキシプロピレングリコール自体は周知であり、市販されているので、市販品を好ましく用いることができる。例えば、「カラリン」の商品名で三洋化成工業から市販されており、中でも「カラリン102」(商品名)を好ましい例として挙げることができる。 As described above, the reagent for measuring complement value of the present invention contains polyalkylene glycol in the reagent so that even if the reagent is stirred immediately before the measurement and foam is generated, it can be quickly eliminated. It is characterized by that. As the polyalkylene glycol, polyoxypropylene glycol is preferable. Since polyoxypropylene glycol itself is well known and commercially available, a commercially available product can be preferably used. For example, it is commercially available from Sanyo Chemical Industries under the trade name of "Kararin", and among them, "Kararin 102" (trade name) can be mentioned as a preferable example.

配合するポリアルキレングリコールの濃度は泡沫を速やかに消去する効果を考慮すると、緩衝液中に感作赤血球又は感作リポソームを含まない試薬全量を基準として、0.0005重量%以上であることが好まく、さらに著しい消泡効果を求めるのであれば0.0025重量%以上が好ましい。一方、試薬の性能への影響を考慮すると、0.01重量%未満が好ましく、0.0095重量%以下がさらに好ましく、0.009重量%以下がさらに好ましい。これらの好ましい範囲の下限値と上限値は、どれとどれを組み合わせてもよい。 The concentration of the polyalkylene glycol to be blended is preferably 0.0005% by weight or more based on the total amount of the reagent containing no sensitized erythrocytes or sensitized liposomes in the buffer solution, considering the effect of quickly eliminating foam. If more remarkable defoaming effect is desired, 0.0025% by weight or more is preferable. On the other hand, considering the influence on the performance of the reagent, it is preferably less than 0.01% by weight, more preferably 0.0095% by weight or less, still more preferably 0.009% by weight or less. Any combination of the lower limit value and the upper limit value of these preferable ranges may be used.

上記したポリアルキレングリコールを含むこと以外は、試薬の組成及びそれを用いた測定方法は従来から使用されているものと同じでよい。すなわち、補体を含む検体を希釈液で希釈した後、感作赤血球を緩衝液中に懸濁させた試薬を希釈した検体を添加し反応させる。検体中の補体価に依存した数の赤血球が溶血するので、遠心処理後、上清の吸光度を測定するか、又は、溶血した赤血球は検体中の補体価に比例し濁度を失うため、波長600~700nmにおける濁度を測定することにより、検体中の補体価を測定することができる。自動化学分析装置では、後者の濁度を測定する方法が広く採用されている。なお、感作赤血球懸濁緩衝液としては、特に限定されないが、アルブミン及びグルコースを含むリン酸緩衝液が用いられており、本発明でもこの緩衝液を好ましく用いることができる。なお、感作赤血球に代えて感作リポソームを用いてもよい。感作リポソームを用いる方法もこの分野において周知である。 Except for containing the above-mentioned polyalkylene glycol, the composition of the reagent and the measuring method using the same may be the same as those conventionally used. That is, after the sample containing complement is diluted with a diluted solution, a sample diluted with a reagent in which sensitized erythrocytes are suspended in a buffer solution is added and reacted. Since the number of erythrocytes depending on the complement value in the sample is hemolyzed, the absorbance of the supernatant is measured after centrifugation, or the hemolyzed erythrocytes lose their turbidity in proportion to the complement value in the sample. By measuring the turbidity at a wavelength of 600 to 700 nm, the complement value in the sample can be measured. In automatic chemical analyzers, the latter method of measuring turbidity is widely adopted. The sensitized erythrocyte suspension buffer is not particularly limited, but a phosphate buffer solution containing albumin and glucose is used, and this buffer solution can also be preferably used in the present invention. In addition, sensitized liposomes may be used instead of sensitized erythrocytes. Methods using sensitized liposomes are also well known in the art.

上記した本発明の補体価測定用試薬を用いて検体中の補体価を測定すると、試薬(赤血球懸濁液)中の赤血球の均一に混和するために試薬を激しく攪拌して泡沫が発生しても、速やかに消去される。上記ポリアルキレングリコールを配合することにより、試薬に生じる泡沫が消去される。従って、本発明は、また、消泡剤としてポリアルキレングリコールを緩衝液に添加することから成る、緩衝液中に懸濁された感作赤血球または感作リポソームを含む補体価測定用試薬に生じる泡沫の消去方法をも提供するものである。 When the complement value in the sample is measured using the above-mentioned complement value measuring reagent of the present invention, the reagent is vigorously stirred to generate bubbles in order to uniformly mix the red blood cells in the reagent (erythrocyte suspension). Even so, it will be erased promptly. By blending the above polyalkylene glycol, bubbles generated in the reagent are eliminated. Accordingly, the present invention also arises in complement titer measurement reagents comprising sensitized erythrocytes or sensitized liposomes suspended in a buffer, comprising adding polyalkylene glycol as an antifoaming agent to the buffer. It also provides a method of eliminating foam.

さらに、下記実施例に具体的に示されるように、ポリアルキレングリコールを含む緩衝液を希釈液として用いると上記本発明の方法を容易に実施できるので、本発明は、緩衝液中にポリアルキレングリコールを含んでなる、補体価測定用希釈液をも提供するものである。 Further, as specifically shown in the following examples, when a buffer solution containing polyalkylene glycol is used as a diluent, the method of the present invention can be easily carried out. Therefore, the present invention has a polyalkylene glycol in the buffer solution. Also provided is a diluted solution for measuring complement titer, which comprises.

以下、本発明を実施例に基づきより具体的に説明する。もっとも、本発明は下記実施例に限定されるものではない。なお、「%」は全て重量%を意味する。 Hereinafter, the present invention will be described in more detail based on examples. However, the present invention is not limited to the following examples. In addition, "%" means all by weight%.

実施例1~4、比較例1
検体希釈液としてゼラチン0.1%、カルシウムイオン及びマグネシウムイオンを含むベロナール緩衝液(濃度:カルシウム0.0022%、マグネシウム0.011%)にカラリン102(商品名)を、下記表1に示す終濃度に添加した。次に各検体希釈液をプラスチックのボトルに分注した後、密栓した。各ボトルを手で激しく振り、泡沫を発生させた後、泡が消えるまでの時間を経過観察した。
Examples 1 to 4, Comparative Example 1
Caralin 102 (trade name) was added to Veronal buffer (concentration: calcium 0.0022%, magnesium 0.011%) containing 0.1% gelatin, calcium ions and magnesium ions as a sample diluent, as shown in Table 1 below. Added to concentration. Next, each sample diluted solution was dispensed into a plastic bottle and then sealed. Each bottle was shaken violently by hand to generate bubbles, and then the time until the bubbles disappeared was followed up.

Figure 0007082544000001
×:消泡性なし、○:消泡性良好、◎:消泡性極めて良好
Figure 0007082544000001
×: No defoaming property, ○: Good defoaming property, ◎: Very good defoaming property

カラリン102(商品名)の濃度が0.0005%以上のときに消泡効果が得られた。特にカラリン102(商品名)の濃度が0.0025%以上のときの効果は消泡するまでの時間が短かった。 The defoaming effect was obtained when the concentration of Caralin 102 (trade name) was 0.0005% or more. In particular, when the concentration of Caralin 102 (trade name) was 0.0025% or more, the effect was that the time until defoaming was short.

実施例5~10、比較例2
アルブミン(濃度0.5%)、グルコース(濃度1%)を含むリン酸緩衝液にヒツジ赤血球に抗体を結合させた感作ヒツジ赤血球(濃度約2%)を懸濁させた。この感作ヒツジ赤血球懸濁液を撹拌した後に自動化学分析装置(日立7180型)にセットし、オートCH50-Lの標準液である標準補体HC「生研」を用い、試料1.5μlに実施例1の試料希釈液を195μl加え試料を希釈し、更に上記赤血球懸濁液23μlを加え、37℃で6分間反応させた後波長660nmにおける濁度を測定し、検量線を描いた。
Examples 5 to 10, Comparative Example 2
Sensitive erythrocytes (concentration about 2%) in which an antibody was bound to sheep erythrocytes were suspended in a phosphate buffer solution containing albumin (concentration 0.5%) and glucose (concentration 1%). After stirring this sensitized sheep erythrocyte suspension, it was set in an automatic chemical analyzer (Hitachi 7180 type), and the standard complement HC "Seiken", which is the standard solution of Auto CH50-L, was used to measure 1.5 μl of the sample. 195 μl of the sample diluent of Example 1 was added to dilute the sample, 23 μl of the above erythrocyte suspension was further added, and the mixture was reacted at 37 ° C. for 6 minutes, and then the turbidity at a wavelength of 660 nm was measured and a calibration line was drawn.

試料希釈液のカラリン102(商品名)の濃度が0%のとき(比較例2)は泡沫が消えずに残っていたため、自動化学分析装置が試薬の液面を正しく感知できずエラーとなり測定不能であった。一方、カラリン102(商品名)濃度が0.0005%(実施例5)、0.0025%(実施例6)、0.009%(実施例7)、0.0095%(実施例8)、0.01%(実施例9)又は0.015%(実施例10)の場合には、泡沫が消え、自動化学分析装置による測定が可能であった。なお、カラリン102(商品名)の濃度が0.095%からやや反応性に影響が表れ、0.01%から測定値に影響が現れた。これはカラリン102(商品名)が高濃度含まれる場合、補体溶血反応を阻害する働きが生じたためと考えられ、またカラリン102(商品名)自体が白濁した液体であることから、高濃度で添加することで希釈液に濁りが生じ、濁度測定に影響を与えたためと考えられる。 When the concentration of Caraline 102 (trade name) in the sample diluent was 0% (Comparative Example 2), the foam did not disappear, so the automatic chemical analyzer could not correctly detect the liquid level of the reagent, resulting in an error and measurement impossible. Met. On the other hand, the caraline 102 (trade name) concentration was 0.0005% (Example 5), 0.0025% (Example 6), 0.009% (Example 7), 0.0095% (Example 8). In the case of 0.01% (Example 9) or 0.015% (Example 10), the foam disappeared and measurement by an automatic chemical analyzer was possible. The concentration of cararin 102 (trade name) was 0.095%, which slightly affected the reactivity, and 0.01%, which affected the measured value. It is considered that this is because when the caralin 102 (trade name) is contained in a high concentration, it has a function of inhibiting the complement hemolysis reaction, and since the caralin 102 (trade name) itself is a cloudy liquid, the concentration is high. It is probable that the addition caused turbidity in the diluted solution, which affected the turbidity measurement.

Claims (9)

緩衝液中に懸濁された感作赤血球または感作リポソームを含む補体価測定用試薬において、ポリアルキレングリコール(ポリエチレングリコールを除く)を含むことを特徴とする補体価測定用試薬。 A reagent for measuring complement value, which comprises polyalkylene glycol (excluding polyethylene glycol) in a reagent for measuring complement value containing sensitized erythrocytes or sensitized liposomes suspended in a buffer solution. 前記ポリアルキレングリコールがポリオキシプロピレングリコールである請求項1記載の試薬。 The reagent according to claim 1, wherein the polyalkylene glycol is polyoxypropylene glycol. 前記ポリアルキレングリコールの濃度が、試薬全量(感作赤血球または感作リポソームを除く)を基準として0.0005重量%以上である請求項1又は2記載の試薬。 The reagent according to claim 1 or 2, wherein the concentration of the polyalkylene glycol is 0.0005% by weight or more based on the total amount of the reagent (excluding sensitized erythrocytes or sensitized liposomes). 消泡剤としてポリアルキレングリコールを緩衝液に添加することから成る、緩衝液中に懸濁された感作赤血球または感作リポソームを含む補体価測定用試薬に生じる泡沫の消去方法。 A method for eliminating foam generated in a complement titer measuring reagent containing sensitized erythrocytes or sensitized liposomes suspended in a buffer solution, which comprises adding polyalkylene glycol as a defoaming agent to the buffer solution. 前記ポリアルキレングリコールがポリオキシプロピレングリコールである請求項4記載の方法。 The method according to claim 4, wherein the polyalkylene glycol is polyoxypropylene glycol. 前記ポリアルキレングリコールの濃度が試薬全量(感作赤血球または感作リポソームを除く)を基準として0.0005重量%以上である請求項4又は5記載の方法。 The method according to claim 4 or 5, wherein the concentration of the polyalkylene glycol is 0.0005% by weight or more based on the total amount of the reagent (excluding sensitized erythrocytes or sensitized liposomes). 緩衝液中にポリアルキレングリコール(ポリエチレングリコールを除く)を含んでなる、補体価測定用検体希釈液。 A sample diluent for measuring complement titer, which contains polyalkylene glycol (excluding polyethylene glycol) in the buffer solution. 前記ポリアルキレングリコールがポリオキシプロピレングリコールである請求項7記載の検体希釈液。 The sample diluent according to claim 7, wherein the polyalkylene glycol is polyoxypropylene glycol. 前記ポリアルキレングリコールの濃度が、検体希釈液全量を基準として0.0005重量%以上である請求項7又は8記載の検体希釈液。 The sample diluent according to claim 7 or 8, wherein the concentration of the polyalkylene glycol is 0.0005% by weight or more based on the total amount of the sample diluent.
JP2018143852A 2018-07-31 2018-07-31 Method for eliminating bubbles generated in the reagent for measuring complement value and the reagent for measuring complement value Active JP7082544B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018143852A JP7082544B2 (en) 2018-07-31 2018-07-31 Method for eliminating bubbles generated in the reagent for measuring complement value and the reagent for measuring complement value

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018143852A JP7082544B2 (en) 2018-07-31 2018-07-31 Method for eliminating bubbles generated in the reagent for measuring complement value and the reagent for measuring complement value

Publications (2)

Publication Number Publication Date
JP2020020639A JP2020020639A (en) 2020-02-06
JP7082544B2 true JP7082544B2 (en) 2022-06-08

Family

ID=69588999

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018143852A Active JP7082544B2 (en) 2018-07-31 2018-07-31 Method for eliminating bubbles generated in the reagent for measuring complement value and the reagent for measuring complement value

Country Status (1)

Country Link
JP (1) JP7082544B2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003507741A (en) 1999-08-23 2003-02-25 ヴェンディア テック コーポレーション リミテッド Blood sample decolorization method, diagnostic method and diagnostic kit using the same
JP2004301612A (en) 2003-03-31 2004-10-28 Denka Seiken Co Ltd Reagent for measuring complement value and method for stabilizing measured complement value using the same
JP2007163182A (en) 2005-12-09 2007-06-28 Fujifilm Corp Hemolytic method and hemolytic reagent
WO2010024325A1 (en) 2008-08-28 2010-03-04 積水メディカル株式会社 Blood collection container
US20110221425A1 (en) 2010-03-09 2011-09-15 Nokia Corporation Apparatus and associated methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02108969A (en) * 1988-10-18 1990-04-20 Kanegafuchi Chem Ind Co Ltd Immunoassay using liposome

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003507741A (en) 1999-08-23 2003-02-25 ヴェンディア テック コーポレーション リミテッド Blood sample decolorization method, diagnostic method and diagnostic kit using the same
JP2004301612A (en) 2003-03-31 2004-10-28 Denka Seiken Co Ltd Reagent for measuring complement value and method for stabilizing measured complement value using the same
JP2007163182A (en) 2005-12-09 2007-06-28 Fujifilm Corp Hemolytic method and hemolytic reagent
WO2010024325A1 (en) 2008-08-28 2010-03-04 積水メディカル株式会社 Blood collection container
US20110221425A1 (en) 2010-03-09 2011-09-15 Nokia Corporation Apparatus and associated methods

Also Published As

Publication number Publication date
JP2020020639A (en) 2020-02-06

Similar Documents

Publication Publication Date Title
wan Azman et al. Hemolyzed specimens: major challenge for identifying and rejecting specimens in clinical laboratories
Glick et al. Unreliable visual estimation of the incidence and amount of turbidity, hemolysis, and icterus in serum from hospitalized patients.
EP2237019B1 (en) Blood analyzer, method and computer program for determining existence and nonexistence of lymphoblasts in blood sample
Mayer et al. Spectrophotometric standardization of complement for fixation tests
Ko et al. Comparison of red blood cell hemolysis using plasma and serum separation tubes for outpatient specimens
NO149864B (en) IMMUNOLOGICAL REAGENT.
JP7082544B2 (en) Method for eliminating bubbles generated in the reagent for measuring complement value and the reagent for measuring complement value
Alauddin et al. HbA2 levels in normal,-thalassaemia and haemoglobin E carriers by capillary electrophoresis
CN110988363A (en) Detection reagent for antiviral protein MxA and preparation method thereof
CN109387410A (en) A kind of TMAO negative sample and the preparation method and application thereof
JP4231721B2 (en) Complement value measuring reagent and method for stabilizing complement value measurement using the same
EP2439533A1 (en) Immunoassay method and reagent therefor
CN115541895A (en) Formula liquid for improving sensitivity of micro-fluidic inverse detection card and application
Plescia et al. A kinetic method for the titration of complement
Bull Recommendations for reference method for the packed cell volume
Thysell A COMPARISON BETWEEN ALBUSTIX, HEMA‐COMBISTIX, LABSTIX, THE SULPHOSALICYLIC‐ACID TEST, HELLER'S NITRIC‐ACID TEST, AND A BIURET METHOD: Diagnosis of Proteinuria
CN104865386A (en) Method, reagent and kit for quantitative determination of NGAL content in human serum
CN106645749B (en) Hemolytic agent and application
Hsi Paroxysmal nocturnal hemoglobinuria testing by flow cytometry: Evaluation of the REDQUANT and CELLQUANT kits
JP2019211449A (en) Complement value measurement reagent and stabilization method of the measured value of complement value using the same
JP6635814B2 (en) Analytical method for trace amounts and unknown body fluids
CN108152177B (en) Method for rapidly detecting hematocrit
CN109283344A (en) A kind of preparation method of kit and its stabilizer for detecting apoA I, apoB
EP4249918A1 (en) Sample analyzer, sample testing method, and glycated hemoglobin testing method
JP2022161884A (en) Method of improving accuracy of automated analyzer measurements

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20200609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210423

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220412

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220502

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220527

R150 Certificate of patent or registration of utility model

Ref document number: 7082544

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150